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Abstract In this report a recombinant bifunctional phospho-
mannose isomerase/GDP-D-mannose pyrophosphorylase from
Helicobacter pylori has been studied. The enzyme catalyzes
the first and third steps of GDP-D-mannose biosynthesis from
D-fructose-6-phosphate. The first step, isomerization from
D-fructose-6-phosphate to D-mannose-6-phosphate, is found to
be rate-limiting in GDP-D-mannose biosynthesis due to feed-
back inhibition. The inhibition is of non-competitive (mixed)
type. As the enzyme is found only in bacteria probably
participating in capsular polysaccharide biosynthesis, it could
be a specific therapeutic target against bacterial infec-
tion. % 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
Phosphomannose isomerase (PMI) catalyzes the intercon-
version of D-fructose-6-phosphate (F6P) and D-mannose-6-
phosphate (M6P). It plays a critical role in the metabolism
of D-mannose and supply of GDP-D-mannose, which is neces-
sary for mannosylation of various structures such as lipopoly-
saccharides (LPS) and glycoproteins. In addition, GDP-D-
mannose is a precursor for other activated sugar nucleotides
including GDP-L-fucose, GDP-colitose, GDP-perosamine and
GDP-D-rhamnose, which are also involved in the synthesis of
various glycoconjugates. Proudfoot et al. [1] de¢ned three
types of PMI. Type I enzymes include all eukaryotic PMIs
identi¢ed so far and the enzymes from Salmonella typhimuri-
um [2] and Escherichia coli (ManA) [3]. The type II enzymes
are bifunctional phosphomannose isomerase/GDP-D-mannose
pyrophosphorylases (PMI/GMPs) found in bacteria such as
Pseudomonas aeruginosa (AlgA) [4], Xanthomonas campestris
(XanB) [5], and S. typhimurium [2,6]. No overall homology is
found between type I and type II enzymes except a very short
PMI motif [7]. The type III group has only one protein from
Rhizobium meliloti [8].
The type I PMIs have been well studied including those
from X. campestris [9], Candida albicans [10] and fungal and
mammalian sources [1,11]. The crystal structure of C. albicans
PMI has been resolved at 1.7 AD resolution. The protein is a
metalloenzyme requiring one atom of zinc that is bound to a
pocket within the catalytic center [12]. The impact of type I
PMIs on pathogenicity has been reported for Cryptococcus
neoformans [13] and Leishmania mexicana [14]. Since the pmi
gene in Saccharomyces cerevisiae [15] and C. albicans [10] is
essential for the biosynthesis of the cell wall, PMI from the
latter is currently being investigated as a target to combat
fungal infections [12,16]. In contrast, the study of type II
bifunctional PMI/GMPs has been quite limited. PMI/GMP
has been detected in several bacteria including P. aeruginosa
(AlgA) [4], S. typhimurium [2,6], X. campestris (XanB) [5] and
Acetobacter xylinum (AceF) [17]. But up to now, the only
PMI/GMP that has been carefully studied is the enzyme
from P. aeruginosa (AlgA), which has been demonstrated to
be composed of two separate domains, an N-terminal GMP
domain and a C-terminal PMI domain [4,18]. It is essential
for the synthesis and accumulation of alginate, an extracellu-
lar glycoconjugate entrapping the bacteria, which enables the
pathogen to resist most antibiotics and evade host immunity.
PMI/GMP catalyzes the ¢rst and third steps in the production
of GDP-D-mannose from F6P, a glycolytic intermediate
(Fig. 1). Since the enzyme stands at a branch point from
the essential central pathway towards glycoconjugate synthe-
sis, it had been expected that the enzyme is well regulated for
metabolic £ow control. Unexpectedly, the study on AlgA
showed no sign of such regulation [4]. Here we will report
for the ¢rst time how Helicobacter pylori PMI/GMP regulates
GDP-D-mannose synthesis through feedback inhibition.
2. Materials and methods
2.1. Bacterial strains and plasmids
E. coli DH5K [lacZvM15 hsdR recA] and BL21(DE3) [F3 ompT
hsdSB(r3Bm
3
B ) gal dcm (DE3)] were from Gibco-BRL and Novagen,
respectively. H. pylori 26695 chromosomal DNA was purchased from
ATCC (ATCC700392D) and plasmid DNA pET15b was bought from
Novagen.
2.2. Chemicals and reagents
Restriction enzymes and T4 DNA ligase were obtained from Prom-
ega. Vent DNA polymerase was purchased from New England Bio-
labs. GTP, GDP-D-mannose, GDP-L-fucose, D-fructose-6-phosphate
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(F6P), D-mannose-1-phosphate (M1P), D-mannose-6-phosphate
(M6P), D-glucose-1,6-bisphosphate, nicotinamide adenine dinucleotide
phosphate (NADPþ), inorganic pyrophosphate (Ppi) and pyrophos-
phatase, phosphomannose isomerase and D-glucose-6-phosphate de-
hydrogenase were products of Sigma. D-Glucose-6-phosphate isomer-
ase was purchased from ICN. Other chemicals were of the highest
grade from commercially available sources.
2.3. Overexpression and puri¢cation of H. pylori PMI/GMP and
phosphomannomutase
The primers used for the ampli¢cation of the PMI/GMP gene were
P1: 5P-GGGAATTCCATATGAAAATTAAAAATATC (NdeI), P2:
5P-GGTACGGATCCTTAGGCGTTTTGATTTTGTC (XhoI) and
the primers for the phosphomannomutase (PMM) gene were P1: 5P-
GGGAATTCCATATGGACATTAGCATTTTTAG (NdeI), P2: 5P-
GGTACGGATCCTTAAAGTTTTTCAATAAATTG (BamHI).
PCR was performed in a total of 50 Wl consisting of 20 mM Tris^
HCl, pH 8.8, 10 mM KCl, 2 mM MgSO4, 10 mM (NH4)2SO4, 0.1%
Triton X-100, 50 ng template DNA, 200 nM P1 and P2 each, 0.2 mM
dNTPs each, and 0.5 U DNA polymerase. After heating at 96‡C for
2 min, 25 cycles were carried out including denaturation at 96‡C
for 20 s, annealing at 55‡C for 30 s and elongation at 72‡C for
1 min followed by a ¢nal elongation of 7 min. The DNA fragment
obtained was inserted downstream of T7 promoter in pET15b. The
E. coli BL21 (DE3) harboring the recombinant plasmid was grown in
LB medium until OD590 reached 0.8. The expression of the protein
was induced by 0.1 mM IPTG at 30‡C for 17 h. The bacteria were
harvested and disrupted by sonication on ice. The lysate was cleared
by centrifugation and loaded onto a Ni-NTA column (Qiagen). Fur-
ther puri¢cation was carried out by FPLC using a HiLoad 16/60
Superdex 200 column (Pharmacia), equilibrated and eluted with
50 mM Tris^HCl bu¡er (pH 7.0) containing 0.2 mM dithiothreitol
(DTT) and 100 mM NaCl. Protein concentration was analyzed by the
Lowry method [19].
2.4. Enzyme activity analysis
Detection of PMI activity was performed at 25‡C in 1 ml of 50 mM
Tris^HCl bu¡er (pH 7.0) containing 2 mM Co2þ, 1 mM M6P, 1 mM
NADPþ, 5 U phosphoglucose isomerase and 5 U phosphoglucose
dehydrogenase. The reduction of NADPþ was followed by monitor-
ing UV absorption at 340 nm. The kinetic study of PMI was per-
formed at varied concentrations of M6P in the presence or absence of
GDP-D-mannose. The kinetic parameters were calculated by plotting
1/v versus 1/[S] (Lineweaver^Burk). The KPi and Ki were obtained by
plotting the reciprocals of apparent maximal velocities and Km/Vmax
against the inhibitor concentration, respectively.
Analysis of GMP forward reaction was performed at 37‡C for 1 min
in 50 mM Tris^HCl bu¡er (pH 7.0) containing 0.2 mM DTT, 2 mM
Mg2þ, 1 mM GTP and 1 mM M1P. Analysis of the reverse reaction
was carried out at 37‡C for 1 min in 50 mM Tris^HCl bu¡er (pH 8.0)
containing 0.2 mM DTT, 2 mM Mg2þ, 1 mM GDP-D-mannose and
1 mM Ppi. To determine the kinetic parameters of GMP, varying
concentrations of either M1P or GDP-D-mannose were used while
the concentration of GTP or Ppi was kept at 1 mM, respectively.
PMM activity was analyzed at 25‡C in 1 ml of 50 mM Tris^HCl
bu¡er (pH 7.0) containing 1 mM Zn2þ, 10 WM glucose-1,6-diphos-
phate, 1 mM M1P, 1 mM NADPþ, 5 U phosphomannose isomerase,
5 U phosphoglucose isomerase and 5 U phosphoglucose dehydro-
genase. Again NADPþ reduction was followed by monitoring
OD340 nm.
2.5. Determination of the rate-limiting step in GDP-D-mannose
biosynthesis
M1P, M6P and F6P were used to synthesize GDP-D-mannose. The
reaction was performed at 37‡C in a reaction mixture containing
50 mM Tris^HCl (pH 7.0), 5 mM MgCl2, 0.2 mM DTT, 10 WM
glucose-1,6-diphosphate, varied concentrations of each precursor
and GTP, 0.1 U/ml inorganic pyrophosphatase, suitable amounts of
PMM and PMI/GMP.
2.6. Analysis of GDP-D-mannose by capillary electrophoresis
Capillary electrophoresis was performed using an ISCO 3850 capil-
lary electropherograph equipped with a UV detector. The capillary
was of bare silica (75 WmU50 cm) with the UV detector mounted at
40 cm of the capillary. The analysis was run in 25 mM sodium tetra-
borate (pH 9.42) at 22 kV/72 WA, and the sugar nucleotide was de-
tected at 254 nm. Peak integration was performed by a HP 3395
integrator.
2.7. Sequence alignment and database search
Sequence alignment was performed by ClustalW. Motif detection
and database search by position-speci¢c scoring matrices were carried
out according to Bailey et al. [20].
3. Results
3.1. Expression and characterization of bifunctional PMI/GMP
from H. pylori
L-Fucose has been found in the LPS O-antigen of H. pylori,
which has been implicated in its pathogenesis and persistence
[21^23]. In our search for the enzymes involved in the fuco-
sylation of the bacterial surface [24], an open reading frame
named HP0043 was found to be highly homologous to PMI/
GMPs from P. aeruginosa (AlgA) (40% amino acid identity)
[4] and X. campestris (XanB) (39% amino acid identity) [5].
Therefore the gene was cloned and overexpressed in E. coli
with an N-terminal His tag. The recombinant protein was
puri¢ed to apparently homogeneity as judged by SDS^
PAGE (Fig. 2). The denatured protein migrated as a single
band at the position corresponding to about 55 kDa, close to
the calculated value (55 303 Da) from the deduced protein
sequence. The puri¢ed protein was subjected to analysis for
both PMI and GMP activities.
M6P was used as the substrate for PMI analysis. The for-
mation of F6P can be detected by monitoring OD340 nm after
being coupled to NADPþ reduction through phosphoglucose
isomerase and phosphoglucose dehydrogenase. Divalent metal
ions are necessary for PMI activity, with an order of activa-
tion being Co2þsMg2þsMn2þsZn2þ when they are
present at 2 mM.
M1P and GDP-D-mannose were used for activity analysis
of GMP forward and reverse reactions, respectively. Mg2þ or
Mn2þ is necessary for both directions although Mn2þ is less
e¡ective (30% of the e⁄ciency with Mg2þ). It is very interest-
ing to ¢nd that pH dependence di¡ers for forward and reverse
directions (data not shown). The forward reaction, with a pH
optimum of 7, is very sensitive to pH £uctuation, while the
reverse reaction rate does not change much in the pH range of
7^9. This might suggest that the enzyme requires proper ion-
ization of either M1P and/or GTP for binding and catalysis.
Fig. 1. The GDP-D-mannose biosynthetic pathway. The enzyme catalyzing each step is shown below the arrow. PMI, phosphomannose isomer-
ase; PMM, phosphomannomutase; GMP, GDP-D-mannose pyrophosphorylase.
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3.2. Identi¢cation of the rate-limiting step in GDP-D-mannose
biosynthesis in vitro
M1P, M6P and F6P were used as precursors to synthesize
GDP-D-mannose (Fig. 3). When M1P or M6P was used in
equal molar ratio to GTP, the reaction completed very
quickly, with approximately 90% of the substrate transformed
into GDP-D-mannose. But if the synthesis started from F6P,
only 9% of the substrate was converted to GDP-D-mannose
under the same condition. The reaction was followed in more
detail and a time pro¢le was constructed (Fig. 4). The pro-
duction of GDP-D-mannose was signi¢cantly improved by
increasing the F6P/GTP molar ratio.
3.3. PMI activity of PMI/GMP is inhibited by
GDP-D-mannose
PMI activity was analyzed in the presence or absence of
various compounds involved in the GDP-D-mannose biosyn-
thetic pathway (Fig. 5A). It was found that PMI activity was
severely inhibited by GDP-D-mannose, the end product of the
pathway, suggesting the existence of feedback inhibition. The
inhibition type was demonstrated to be non-competitive
(mixed) as both apparent Km and Vmax were changed in the
presence of GDP-D-mannose (Fig. 5B). The Ki and KPi were
25.50V 0.67 WM and 96.86V 0.98 WM, respectively.
3.4. PMI/GMPs are present only in bacteria based on sequence
alignment and database search
Amino acid sequence alignment of HP0043 with AlgA and
XanB (Fig. 6), two other con¢rmed bifunctional PMI/GMP
enzymes, revealed that all of them have at their N-terminal a
highly conserved region containing a pyrophosphorylase sig-
Fig. 2. SDS^PAGE analysis of puri¢ed PMI/GMP. SDS^PAGE
was run in 12% polyacrylamide gel. Lane 1, molecular weight
marker; lane 2, puri¢ed PMI/GMP.
Fig. 3. Synthesis of GDP-D-mannose using intermediates from dif-
ferent stages of the pathway. M1P, M6P and F6P at 5 mM were
used to react with 5 mM GTP. The reaction was carried out at
37‡C for 2 h. GDP-D-mannose yield (%) was based on GTP (mol/
mol).
Fig. 4. Pro¢le of GDP-D-mannose synthesis with varied F6P/GTP
molar ratios. F6P at 5 mM and 15 mM was used to react with
GTP (5 mM). The reaction was carried out at 37‡C. GDP-D-man-
nose yield (%) was based on GTP (mol/mol). See Section 2 for de-
tails.
Fig. 5. A: Inhibition of PMI activity by GDP-D-mannose. PMI ac-
tivity was analyzed in the presence of 0.5 mM of GDP-L-fucose
(GDP-fuc), GDP-D-mannose (GDP-man), GTP, M1P and Ppi. Rel-
ative activity (%) was calculated against control (100%), the PMI
activity measured without the presence of the above-mentioned com-
pounds. B: Double reciprocal plot at various inhibitor concentra-
tions. The inhibitor concentrations are shown above the plot.
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nature sequence, GXGXR(L)-PK. In addition, three separate
motifs were detected by position-speci¢c scoring matrices.
Motif 3 was found in the GMP domain while motifs 1 and
2, closely linked, were found in the PMI domain. The posi-
tion-dependent scoring matrices corresponding to the three
motifs were used by MAST [20] programs to perform data-
base search and 69 protein sequences containing the three
motifs were retrieved with E values ranging from 3.2e-156
to 3.9e-52. The E value of a sequence is the expected number
of sequences in a random database of the same size that
would match the motifs as well as the sequence does [20].
Obviously, all these sequences are very speci¢c as judged
from their extremely low E values and therefore are most
likely type II bifunctional enzymes. Most importantly it was
also found that all these proteins exist only in bacteria.
4. Discussion
In this study we have identi¢ed and characterized H. pylori
HP0043 as a bifunctional PMI/GMP. Our results show a
nearly absolute requirement for divalent ions by the enzyme.
While GMP activity depends solely on Mg2þ or Mn2þ, PMI
activity can use a variety of metal ions with Co2þ as the most
e¡ective activator and Zn2þ as the least among the divalent
ions tested. This suggests that the combination between the
metal ion and the PMI domain of PMI/GMP is loose and less
speci¢c, which is in sharp contrast to type I PMI, a metal-
loenzyme containing one atom of zinc per protein molecule
[12,25]. But sequence alignment and domain analysis (Fig. 6)
reveal that the PMI domain of the bifunctional enzymes still
conserves the zinc binding pattern, e.g. QXH (X represents
any amino acid) as seen in zinc metalloenzymes [26] including
type I PMIs. The reason why the PMI domain of PMI/GMPs
does not speci¢cally bind Zn2þ is unknown. The apparent Km
of recombinant H. pylori PMI/GMP for M6P is signi¢cantly
lower than that of AlgA (55.56 WM against 3.03 mM). The
high Km of AlgA for M6P has been proposed to be in favor of
M6P formation, and therefore to be well suited for alginate
production but not for D-mannose utilization by P. aeruginosa
[4]. If this is true for P. aeruginosa, then H. pylori might have
a well-balanced bi-directional pathway as suggested by the
close values of Kcat/Km for M6P, M1P and GDP-D-mannose
(Table 1). H. pylori di¡ers from P. aeruginosa in that it does
not need to accumulate huge amounts of a single metabolite
like alginate from the pathway. This might also help to ex-
plain why AlgA does not exhibit feedback inhibition [4],
which would make it possible to produce alginate continu-
ously.
Fig. 6. Amino acid sequence alignment and motif analysis of bifunctional PMI/GMPs. HP0043 (AAD07111) from H. pylori was aligned with
PMI/GMPs from P. aeruginosa (AlgA) (P07874) and X. campestris (XanB) (P29956). Identical amino acids are represented by dots. GMP do-
main and PMI domain are marked by arrows. Pyrophosphorylase signature sequences and three motifs are boxed. The underlined region within
motif 1 is the consensus sequence shared by type I and type II PMIs.
Table 1
Kinetic parameters of recombinant H. pylori PMI/GMP
M6P M1P GDP-D-mannose
Km (WM) 55.56V 0.96 22.08V0.94 101V 0.93
Kcat (s31) 6.14V 0.32 10.27V0.42 43.38V 0.40
Kcat/Km (WM31 s31) 0.11 0.47 0.43
See Section 2 for detailed description of activity analysis.
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As shown in Fig. 1, the major pathway for GDP-D-man-
nose biosynthesis starts from F6P, consisting of three steps
with two intermediates, M6P and M1P. Combined use of
recombinant PMI/GMP and PMM allows us to synthesize
GDP-D-mannose from intermediates of di¡erent stages, which
leads to the ¢nding that the ¢rst step, isomerization of F6P to
M6P, is rate-limiting (Fig. 3). Di¡erent concentrations of sub-
strates and enzymes have been tested to remove any artifacts
caused by selection of reaction conditions. Another possibility
is that F6P could block one step of the pathway, but it is less
likely since the production of GDP-D-mannose is greatly im-
proved by increasing F6P/GTP molar ratio (Fig. 4). As PMI/
GMP catalyzes the ¢rst and third steps of the pathway
(Fig. 1), the enzyme is actually interacting with all the inter-
mediates involved in GDP-D-mannose biosynthesis and it is
reasonable to believe that some of them might participate in
the regulation of the enzyme. PMI activity analysis in the
presence of various intermediates from the pathway shows
that GDP-D-mannose, the end product of the pathway, se-
verely inhibits PMI activity (Fig. 5A). Therefore the bottle-
neck is caused by feedback inhibition of PMI activity via
GDP-D-mannose. As there is no indication that GDP-D-man-
nose could bind to the PMI domain, this suggests that
although separate domains specify PMI and GMP activities,
binding of GDP-D-mannose to the GMP domain can greatly
in£uence the substrate binding as well as the catalytic activity
of the PMI domain. On the other hand, the di¡erence between
Ki and KPi (25.50 WM versus 96.86 WM) indicates that binding
of M6P with the PMI domain can decrease the a⁄nity be-
tween GMP domain and GDP-D-mannose. These results are
consistent with the observation that Ser12 and Val321 muta-
tions in AlgA severely deteriorate both PMI and GMP activ-
ities by disrupting an important structure required for both
PMI and GMP activities [18].
The feedback control in the biosynthesis of sugar nucleo-
tides has been well studied for the inhibition of D-glucose-1-
phosphate thymidyltransferase by dTDP-L-rhamnose via the
competitive and non-competitive manner [27,28]. The compet-
itive inhibition is caused by binding of dTDP-L-rhamnose to
the same sites in roughly the same manner as the substrates in
both forward and reverse directions while the mechanism for
non-competitive inhibition is less clear [27]. It has also been
reported that CMP-N-acetylneuraminic acid (CMP-Neu5Ac)
inhibits the UDP-GlcNAc 2-epimerase activity of bifunctional
UDP-GlcNAc 2-epimerase/ManNAc kinase in rat liver, cata-
lyzing the ¢rst and second reactions of CMP-Neu5Ac biosyn-
thesis from UDP-GlcNAc [29]. But CMP-Neu5Ac is not an
immediate substrate or product of the bifunctional enzyme.
The PMI/GMP reported here obviously presents a new con-
trol mechanism for sugar nucleotide biosynthesis. It is also
di¡erent from the most extensively studied bifunctional en-
zyme, chorismate mutase-prephenate dehydratase (P-protein),
which plays a critical role in the biosynthesis of aromatic
acids. The P-protein, like PMI/GMP, has two distinct cata-
lytic domains for chorismate mutase and prephenate dehydra-
tase, respectively. But it also has an extra regulatory domain
(R-domain) for binding and feedback inhibition by phenyl-
alanine [30,31]. Another bifunctional enzyme, 6-phosphofruc-
to-2-kinase/fructose-2,6-bisphosphatase, a¡ects glucose me-
tabolism through its ability to both synthesize and degrade
fructose-2,6-bisphosphate. The kinase activity of the bifunc-
tional protein is feedback-inhibited by speci¢c binding of suc-
cinate, a citric acid cycle intermediate, to the kinase domain
[32]. A similar mechanism has also been reported for feedback
inhibition by proline of the Q-glutamyl kinase activity of bi-
functional Q-glutamyl kinase/Q-glutamyl phosphate reductase,
catalyzing the ¢rst two steps of proline biosynthesis from
glutamate in plant [33].
Sequence alignment and database search reveals that all
PMI/GMP bifunctional proteins, either experimentally con-
¢rmed or putative based on sequence analysis, are highly ho-
mologous, possessing two separate domains containing three
conserved motifs (Fig. 6). The GMP domain also shows over-
all homology to monofunctional GMP enzymes (data not
shown) and it appears that motif 3 is highly conserved among
them, containing Lys175 that has been shown to participate in
M1P binding as well as in catalysis [18,27]. On the other hand,
the PMI domain of type II bifunctional enzymes shares no
homology with type I PMI proteins except a very short con-
sensus sequence of nine amino acids within motif 1, contain-
ing the completely conserved residues like Gln389 and His391
that are found at the active site of C. albicans PMI [7,12].
Motif 2 is located close to the C-terminus of the bifunctional
proteins. The requirement of motif 2 for PMI activity can be
inferred from the observation that the 52-kDa chymotryptic
fragment of AlgA (deletion of C-terminus by about 1 kDa)
retained only 8% of the PMI activity of the undigested protein
but retained 81% of the GMP activity of the intact protein
[18]. It is also supported by the ¢nding that the insertion at
the corresponding site of XanB abolishes PMI activity but
maintains 40% of the wild-type GMP activity [5].
As the impact of type I PMIs on pathogenicity has been
implicated [13,14], PMI of pathogenic C. albicans has become
a potential target to combat fungal infections [12,16]. How-
ever, due to the high level of sequence identity (s 40%)
among type I PMI enzymes from bacteria to human beings
[11], it might be very di⁄cult to achieve species-speci¢c inhi-
bition of PMI. On the other hand, database searching using
the three motifs found in PMI/GMPs shows that proteins
containing all three motifs (con¢rmed or putative type II
PMIs) are only found in bacteria. It has been suggested that
type I enzymes participate in mannose metabolism while type
II enzymes function in capsular polysaccharide biosynthesis
[1]. Therefore type II PMIs can be a speci¢c target to ¢ght
bacterial infection. Further work including site-directed muta-
genesis and crystallization will be needed to clarify the cata-
lytic and regulatory mechanism of PMI/GMPs, which will
lead to rational design of highly e⁄cient and speci¢c inhib-
itors.
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